Top 20 of Dyskinesia, Drug-Induced

Article title # Publications/# Citations

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

2003: CArdouin; ABatir; ALBenabid; ABenazzouz; SChabardès; VFraix; AKoudsie; PKrack; ... JFLeBas; PDLimousin; PPollak; NVan Blercom;


Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.

1998: CArdouin; ALBenabid; ABenazzouz; DHoffmann; PKrack; PLimousin; PPollak;


Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.

2003: GBernardi; PCalabresi; MACenci; DCentonze; GFisone; PGreengard; KHåkansson; BPicconi;


The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.

1987: UGAhlfors; PBech; SJDencker; KElgen; OLingjaerde;


A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

2000: DJBrooks; CEClarke; PPDe Deyn; ADKorczyn; AELang; ORascol;


Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.

2005: YAgid; AAlbanese; ALBenabid; AMBonnet; MFContarino; VFraix; AGironell; JGuridi; ... MIHariz; JLHoueto; JKulisevsky; AELang; AMLozano; JMolet; JAObeso; BPascual-Sedano; BPidoux; PPollak; NPQuinn; SRehncrona; MCRodriguez-Oroz; LRomito; JSaint-Cyr; MScerrati; JDSpeelman; NVan Blercom; JVolkmann; JXie; IZamarbide;


Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

2007: ABjörklund; TCarlsson; MCarta; DKirik;


Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors.

2010: HSBateup; SBirnbaum; GFisone; PGreengard; EJNestler; ESantini; WShen; DJSurmeier; EValjent;


Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

2001: JEAhlskog; MDMuenter;


L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.

1998: ABjörklund; MACenci; CSLee;


A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.

2006: MAGeyer; MGhajarnia; AAGrace; JDJentsch; HMoore;


Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

2002: MAndersson; MACenci; DKirik; MLundblad; NWierup; CWinkler;


Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

2004: CUCorrell; JMKane; SLeucht;


D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.

2005: JDAxelrod; SBarghshoon; CKChen; BNCheyette; JEbert; AKovoor; HALester; JSchwarz; ... SSchwarz; PSeyffarth; MISimon;


The serotonin syndrome.

1991: HSternbach;


Pathophysiology of the basal ganglia in Parkinson's disease.

2000: JArtieda; NGonzalo; JLLanciego; JAObeso; CWOlanow; MRodríguez; MCRodriguez-Oroz;


A highly reproducible rotenone model of Parkinson's disease.

2009: JRCannon; REDrolet; JTGreenamyre; ASHonick; HMNa; VTapias;


Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.

2007: ABorgkvist; MCarta; GFisone; JAGirault; PGreengard; DHervé; ESantini; AUsiello; EValjent;


Research diagnoses for tardive dyskinesia.

1982: JMKane; NRSchooler;


Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.

2003: EBezard; TBoraud; SFerry; CGross; LLeriche; UMach; PSokoloff; HStark;